Category: Health

New research published in The BMJ questions the effectiveness of calcium and vitamin D supplements in preventing fractures and falls among healthy older adults.

For decades, older adults have been advised to take daily calcium and vitamin D supplements to strengthen their bones and reduce the risk of fractures and falls. However, a significant new systematic review and meta-analysis published in The BMJ challenges this long-standing medical guidance. The study analyzed data from 69 randomized controlled trials involving nearly 154,000 participants, revealing that these widely used supplements may provide little to no clinically meaningful benefit for most older adults in the general population.

The research, conducted by a Canadian team, aimed to clarify the real-world impact of calcium and vitamin D supplementation on bone health. While these nutrients are essential for bone metabolism, the review found that for community-dwelling older adults who are not already receiving treatment for osteoporosis, routine supplementation does not significantly reduce the risk of hip, vertebral, or other fractures.

Moreover, the findings indicated that the supplements do not meaningfully decrease the frequency of falls, which are a major cause of injury and loss of independence among seniors. The researchers concluded, “These findings do not support routine supplementation with calcium or vitamin D, or combined supplementation to prevent fractures and falls.” Given the widespread nature of this practice and the significant increase in supplement prescriptions in recent years, the team is urging clinicians, guideline panels, and regulatory agencies to fundamentally re-evaluate their current recommendations.

Despite the concerning results of the review, health experts stress that these findings should not be interpreted as a blanket dismissal of the importance of calcium and vitamin D. The study authors noted that the results may not apply to individuals with specific bone disorders, those living in high-risk residential care settings, or patients currently undergoing drug treatment for osteoporosis.

Professor Emma L. Duncan of King’s College London emphasized that for patients who have already experienced a fragility fracture or have a confirmed diagnosis of osteoporosis, these nutrients remain crucial for bone health management. “If you are in a higher risk group, you certainly need enough calcium and vitamin D for bone health,” Duncan stated, advising patients to consult their healthcare providers before making any changes to their supplement regimen.

The study’s findings suggest a potential shift in how medical professionals should approach fall and fracture prevention. Rather than relying on a “magic pill” approach, the authors advocate for redirecting focus and funding toward interventions that have demonstrated clearer benefits. Experts increasingly emphasize the importance of “meaningful prevention” strategies, such as targeted balance and resistance training exercises, which help maintain muscle mass, coordination, and overall physical stability as individuals age.

As the medical community processes this new evidence, the key takeaway for older adults is to prioritize a balanced, nutrient-rich diet and engage in physical activities that promote strength. While the notion of a “supplement for every senior” may be waning, the importance of proactive, evidence-based strategies for maintaining bone health remains as critical as ever. The findings from this study could reshape the conversation around supplementation and encourage a more holistic approach to health in older adults, focusing on lifestyle changes that foster long-term well-being.

These insights are crucial for understanding the evolving landscape of bone health recommendations and the need for personalized approaches to supplementation and preventive care.

According to The BMJ, the implications of this study could lead to significant changes in clinical practice and public health guidelines regarding the use of calcium and vitamin D supplements among older adults.

Dr. Veena Shankaran has been appointed the inaugural holder of the Lert Family Endowed Chair at the Fred Hutch Cancer Center, focusing on the financial challenges faced by cancer patients.

Dr. Veena Shankaran, a prominent medical oncologist and healthcare economics researcher of Indian descent, has been named the inaugural holder of the newly established Lert Family Endowed Chair at the Fred Hutch Cancer Center in Seattle.

This appointment, part of the University of Washington Medicine’s cancer program, recognizes Shankaran’s extensive research into the financial hardships, often referred to as “financial toxicity,” that cancer treatments impose on patients and their families.

The endowed chair was created by Randy Lert, an esophageal cancer patient who received treatment under Shankaran’s care, and his wife, Joyce. Grateful for the honest and high-quality care they received, the Lerts established this chair to fund solutions for patients who encounter significant economic barriers when navigating a cancer diagnosis.

Shankaran’s academic credentials include a Bachelor of Arts in Philosophy from Dartmouth College and a Medical Degree from the University of Michigan Medical School. She completed her residency in internal medicine at the University of Michigan and pursued a fellowship in hematology-oncology at Northwestern University. Currently, she serves as a professor at both Fred Hutch and the University of Washington School of Medicine.

As co-director of the Hutchinson Institute for Cancer Outcomes Research (HICOR), Shankaran was inspired to delve into health economics early in her career. Her focus shifted toward addressing structural inequities after encountering a patient who was secretly rationing his prescribed medication due to its cost, which adversely affected his treatment outcomes.

At HICOR, Shankaran and her research team integrate cancer registry data with healthcare claims and financial records to analyze how economic pressures influence patient survival and quality of life. Her work examines systemic issues, including medical debt, food insecurity, transportation challenges, and childcare needs.

Recently, her team investigated whether credit report data could assist healthcare providers in identifying financially distressed patients earlier than traditional surveys allow.

In addition, she leads a significant multi-site study through the SWOG Cancer Research Network, which found that nearly three-quarters of colon cancer patients experience severe financial distress during their treatment.

The flexible funding provided by the Lert Family Endowed Chair will enable Shankaran’s team to explore innovative, higher-risk ideas, pilot localized interventions, and expedite the process from concept to actionable results. It will also support the mentorship and training of future clinicians and health services researchers.

“Dr. Shankaran has been a leading force at Fred Hutch and nationally for decades,” said Fred Hutch President and Director Dr. Thomas J. Lynch Jr. He emphasized that her commitment to the economics of medicine ensures that scientific breakthroughs effectively translate into real-world benefits for patients.

For the Lert family, this gift represents an investment in systemic transformation. Randy Lert expressed that while he had the personal financial security to manage his illness, he hopes these funds will enhance healthcare delivery, allowing future patients facing similar diagnoses to achieve better outcomes.

According to The American Bazaar, Dr. Shankaran’s work is poised to make a significant impact on the lives of cancer patients grappling with financial challenges.

A new study suggests that the diabetes drug dapagliflozin may significantly reduce the risk of heart failure in individuals with specific genetic variants associated with cardiomyopathy.

A recent study published in Nature Medicine has revealed that dapagliflozin, a medication commonly used to treat type 2 diabetes, may help prevent heart failure in patients with genetic variants linked to cardiomyopathy, a progressive disease affecting the heart muscle.

Researchers from Harvard Medical School, Mass General Brigham, and MIT conducted the study using data from the DECLARE-TIMI 58 trial, which involved over 12,000 adults diagnosed with type 2 diabetes and at heightened risk for cardiovascular issues.

Among the participants, approximately 121 individuals carried inherited gene variants that could increase their likelihood of developing cardiomyopathy. The findings indicated that after a median follow-up of 4.2 years, dapagliflozin significantly reduced hospitalizations for heart failure among those with the genetic variants compared to those without.

While dapagliflozin was effective in lowering heart failure hospitalizations in both groups, the reduction was approximately eight times more pronounced in carriers of the genetic variant. Specifically, among the 82% of carriers without a prior history of heart failure, 12.8% in the placebo group developed heart failure, whereas no heart-failure events were reported among those receiving dapagliflozin.

Co-lead study author Dr. Shinwan Kany, a visiting scientist at the Cardiovascular Research Center with Mass General Brigham Heart and Vascular Institute and the Broad Institute, emphasized the implications of these findings for preventive care. “Historically, identifying a genetic variant for cardiomyopathy mostly meant telling a patient they were at high risk and not having a specific preventive therapy to offer,” he stated in a press release. “These data show we do have tools to lower risk in these individuals.”

Experts caution that while the results are promising, they require further validation due to the limited sample size of carriers in the study. Dr. Andrew Freeman, a cardiologist at National Jewish Health who was not involved in the research, described the findings as “important and provocative.” He noted that participants without a history of heart failure who took dapagliflozin were less likely to develop the condition, suggesting that SGLT2 inhibitors could serve as a preventive therapy for genetically high-risk individuals.

Freeman added, “This should be viewed as an exciting hypothesis-generating finding, not yet a practice-changing mandate for all patients with these genetic variants.” He highlighted that SGLT2 inhibitors are already recognized as foundational medications for cardiovascular and kidney protection.

These medications have been shown to reduce heart failure hospitalizations across a diverse range of patients, including those with diabetes, chronic kidney disease, and established heart failure. The current study introduces the potential for genetic information to help identify a subgroup of patients who may benefit significantly from early treatment.

Genetic testing for cardiomyopathy is often employed for diagnosis, family screening, and risk stratification. If future clinical trials confirm these findings, cardiologists may be able to utilize genetic screening to identify high-risk patients, monitor them more closely, and initiate treatments such as SGLT2 inhibitors before the onset of heart failure symptoms.

Freeman noted that heart failure does not always manifest with symptoms immediately; in some cases, the risk may be present years earlier due to inherited genetic factors. Preventive cardiology could play a crucial role in identifying high-risk patients before they experience symptoms such as shortness of breath, fluid retention, or the need for hospitalization.

As always, the decision to medicate should be made in consultation with a healthcare professional, particularly for individuals with a personal or family history of cardiovascular events. This study represents a significant step toward more personalized and effective preventive strategies in cardiology.

According to Fox News, the findings underscore the potential for integrating genetic insights into clinical practice, paving the way for more targeted interventions in the management of heart failure risk.

Researchers are uncovering new insights into the effects of GLP-1 medications like Ozempic and Wegovy on weight loss and overall health as their use becomes increasingly widespread.

As the popularity of GLP-1 medications such as Ozempic and Wegovy continues to rise, researchers are gaining unprecedented insights into their effects on weight loss and overall health. Tens of millions of individuals around the world are currently using these medications, prompting a unique real-time analysis of their impact on weight management, metabolism, and general well-being. This surge in usage has provided researchers with a substantial dataset that surpasses the findings typically available from controlled clinical trials.

The developments surrounding GLP-1 medications were discussed at the American Diabetes Association (ADA) Scientific Sessions conference held in New Orleans, where experts gathered to share their latest findings. Dr. Melanie Jay, director of the NYU Langone Comprehensive Program on Obesity, emphasized that the rapid adoption of these drugs has led to an unprecedented learning curve for both practitioners and patients. “Usually when a new medicine happens, we have time to learn how to use it,” she said. “But with GLP-1 drugs, everyone is kind of iterating in real time.”

One of the key findings regarding the use of GLP-1 medications is the pattern of weight regain after discontinuation. Clinical trials have shown that patients typically lose between 15 to 20 percent of their body weight over approximately 72 weeks. However, real-world studies have presented a wider range, with weight loss varying from 8 to 17 percent depending on the specific drug and study parameters.

While many users experience weight regain after stopping the medication, some studies indicate that a significant portion of patients can maintain at least part of their weight loss. An analysis involving over 180,000 patients revealed that more than half who used semaglutide (the active ingredient in Wegovy) or tirzepatide (found in Zepbound) managed to either maintain their weight loss or even lose additional weight two years after discontinuation. Hamlet Gasoyan, a researcher at the Center for Value-Based Care Research at the Cleveland Clinic, explained that patients often adopt alternative strategies, such as rigorous exercise or bariatric surgery, to sustain their weight loss.

Notably, the effectiveness of GLP-1 medications varies among individuals. Current research indicates that approximately 10 percent of patients are classified as “non-responders,” losing less than 5 percent of their body weight. Conversely, a subset of patients, termed “super-responders,” lose significant amounts of weight in a relatively short timeframe, although the prevalence of this group remains unclear. Experts suggest that genetic factors and individual differences in the enjoyment derived from eating may contribute to these divergent responses.

While many patients report typical side effects such as nausea, fatigue, and gastrointestinal issues related to GLP-1 medications, the expansive user base has led to the emergence of additional, less common concerns. Social media has highlighted phenomena like “Ozempic breath” and “Ozempic face,” which refer to dehydration and aesthetic changes resulting from fat loss, respectively.

Dr. Scott Hagan, an associate professor of medicine at the University of Washington, noted that some patients have reported hair loss, potentially linked to rapid weight reduction. Moreover, some studies suggest a slight association between GLP-1 medications and the development of rare eye conditions, though causation has yet to be established. There is also concern about the potential for nutritional deficiencies among patients whose appetite is suppressed to extreme levels. While rare, there is a documented increase in the risk of pancreatitis associated with these medications.

The determination of the appropriate dosage for GLP-1 medications remains an area of active discussion among healthcare professionals. Patients typically begin treatment at a low dose, gradually increasing it over time. Although higher doses are often correlated with greater weight loss and improved blood sugar regulation, excessive dosing can suppress appetite to unhealthy levels, potentially leading to nutritional deficits and other adverse health outcomes.

As the popularity of GLP-1 drugs continues to rise, anecdotal evidence suggests that these medications may also influence patients’ personal lives and mental health. Some users report positive changes, such as increased confidence and enhanced physical activity, while others express concerns regarding diminished pleasure in eating and emotional well-being. Marie Spreckley, a researcher at the University of Cambridge, has noted that some patients feel emotionally flat and less connected to the social aspects of dining. These subjective experiences warrant further scientific inquiry.

Since the introduction of Ozempic to the market less than a decade ago, the landscape of weight management and metabolic health has begun to shift dramatically. As the body of research continues to grow, the healthcare community anticipates further revelations about the long-term implications of GLP-1 medications on health, lifestyle, and psychological well-being, according to Source Name.

The keto diet may offer significant benefits for individuals suffering from anorexia nervosa, according to new research from UC San Diego.

New research from the UC San Diego School of Medicine suggests that the ketogenic diet may help alleviate symptoms of anorexia nervosa. The study, published in the journal Nature, involved 22 women aged 18 to 45 who had a history of anorexia nervosa and a body mass index (BMI) above 17.5.

Anorexia nervosa (AN) is a serious psychiatric disorder characterized by severe food restriction and low body weight. Individuals with this condition often experience body dissatisfaction, an intense fear of eating, and a preoccupation with body shape and size, even after weight restoration.

The participants in the study adhered to a ketogenic therapy plan for 14 weeks, aiming for a diet composed of 70% fat, 20% protein, and 10% carbohydrates. The objective was to maintain weight while inducing nutritional ketosis, a metabolic state where the body produces and utilizes ketones for energy due to low carbohydrate intake.

Throughout the study, researchers monitored participants through ketone testing, weekly weight checks, symptom questionnaires, and nutritional and psychiatric support. Among the 18 participants who completed the study, improvements were noted in various areas related to eating disorder symptoms, including restraint, depression scores, and concerns regarding eating, shape, and weight.

Overall scores on the Eating Disorder Examination Questionnaire (EDE-Q) showed significant improvement, with 72% of participants scoring within the recovered or normal range. Importantly, participants’ body weight remained stable, and no BMI fell below the critical threshold of 17.5.

Those who continued to follow the ketogenic therapy three months post-intervention exhibited slightly better EDE-Q scores, indicating ongoing benefits from the dietary approach. The study authors concluded that ketogenic dietary therapy is “well-tolerated” and shows “potential efficacy” in reducing symptoms of anorexia nervosa among adults who are mildly underweight or weight-restored.

Despite these promising findings, the authors acknowledged that the small sample size, which predominantly consisted of White females, limits the generalizability of the results. They emphasized the need for future research to replicate these findings in more diverse populations and to incorporate objective assessments of brain function, such as metabolic PET imaging, to evaluate brain glucose metabolism.

Lead study author Dr. Guido Frank, a professor of psychiatry at UC San Diego School of Medicine, has dedicated over 25 years to studying and treating patients with anorexia. He initiated this study to expand treatment options for this high-risk population, stating that new approaches to anorexia nervosa are “urgently” needed.

Dr. Frank noted, “Our work with ketogenic therapy looks beyond standard therapies and potentially at the underlying physiology of the disorder.” He highlighted the growing evidence linking anorexia nervosa to neurometabolic dysfunction, expressing hope that direct metabolic intervention could help regulate neural function and address the psychological symptoms experienced by patients.

As the conversation around effective treatments for anorexia nervosa continues, this research opens the door to exploring alternative dietary interventions that may provide relief for those affected by this challenging condition, according to Fox News.

A new mRNA melanoma vaccine developed by Merck and Moderna has demonstrated significant long-term benefits, reducing the risk of cancer recurrence or death by nearly 50% over five years.

A novel mRNA melanoma vaccine, known as intismeran autogene, has shown promising results in reducing melanoma risk over a five-year period. This personalized cancer therapy, developed through a collaboration between Merck and Moderna, was presented during the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on May 27.

The findings stem from the phase 2b KEYNOTE-942 study, which reported that the combination of intismeran autogene and the immunotherapy drug KEYTRUDA (pembrolizumab) reduced the risk of cancer recurrence or death by 49% compared to patients who received pembrolizumab alone.

Researchers analyzed data from 157 patients diagnosed with high-risk stage 3 and 4 melanoma, all of whom had undergone surgical removal of their tumors. Participants were divided into two groups: one received the combination therapy, while the other was treated solely with pembrolizumab. The results indicated that the benefits of the combination therapy were “sustained and durable over time.”

Intismeran autogene is engineered using mutations identified in a patient’s own tumor, aiming to educate the immune system on how to recognize and attack the cancer cells effectively.

According to the researchers, the personalized mRNA vaccine combined with KEYTRUDA is “well-tolerated” and has a “manageable” safety profile. Common side effects reported included fatigue, injection-site pain, chills, fever, and headache. Notably, there were no new long-term safety concerns or severe vaccine-related adverse events reported.

The combination therapy is currently undergoing evaluation in a phase 3 study, which represents the final confirmation stage before potential approval.

In a press release from Merck in January, Dr. Kyle Holen, senior vice president and head of development for oncology and therapeutics at Moderna, emphasized the significance of the data, stating it highlights the “potential of a prolonged benefit … in patients with resected high-risk melanoma.” He added that the company continues to invest in its oncology platform due to encouraging outcomes that demonstrate mRNA’s potential in cancer care.

Dr. Marjorie Green, senior vice president and head of oncology global clinical development at Merck Research Laboratories, remarked on the importance of the findings, noting that many patients with stage 3 or 4 melanoma face a “significant risk of recurrence following surgery.” She described the demonstration of the longer-term potential of intismeran autogene and KEYTRUDA to reduce recurrence risk as a “meaningful milestone.”

The company has cited encouraging five-year follow-up data and is looking forward to results from the upcoming late-stage INTerpath trial, which will evaluate the combination therapy in several difficult-to-treat cancers.

As the field of cancer treatment continues to evolve, the promising results of the intismeran autogene vaccine may represent a significant step forward in the fight against melanoma and potentially other cancers, according to Fox News.

Dr. Samir M. Parikh, an esteemed Indian American nephrologist, has been appointed Chair of the Department of Internal Medicine at UT Southwestern Medical Center, effective June 15.

Dr. Samir M. Parikh, a prominent Indian American nephrologist, is set to assume the role of Chair of the Department of Internal Medicine at UT Southwestern Medical Center in Dallas, Texas, starting June 15. In this prestigious position, he will oversee a department comprising nearly 900 faculty members and manage a residency program that ranks as the second largest in the nation.

Under Dr. Parikh’s leadership, the department will benefit from substantial funding, with more than $108 million allocated from the National Institutes of Health (NIH) for the fiscal year 2025. He will also hold the Donald W. Seldin Distinguished Chair in Internal Medicine and the Ruth W. and Milton P. Levy Sr. Chair in Molecular Nephrology, as announced in a university release.

Currently, Dr. Parikh serves as a Professor and Chief of the Division of Nephrology at UT Southwestern, a position he has held since joining the institution in 2021. He also has a secondary appointment in the Department of Pharmacology.

Dr. Parikh earned his bachelor’s degree in chemistry from Harvard College, graduating magna cum laude. He obtained his medical degree from Vanderbilt University and completed his internal medicine residency, along with research and clinical fellowships in nephrology, at Beth Israel Deaconess Medical Center. There, he was recognized as a Harvard Medical School Fellow in General Medicine.

His academic career began at Harvard, where he advanced to the position of Professor of Medicine. He also served as Co-Director of the Center for Vascular Biology Research and held the role of Associate Vice Chair for Research in the Department of Medicine at Beth Israel Deaconess.

In his clinical practice, Dr. Parikh specializes in acute kidney injury and chronic kidney disease. His research over the past two decades has concentrated on the mechanisms of aging in the vasculature, kidneys, and energy metabolism.

Dr. Parikh’s laboratory has garnered over $40 million in funding from the NIH and other sources, and his research findings have been published in prestigious journals, including *Science*, *Nature*, *Nature Medicine*, and *Cell Metabolism*.

In addition to his research and clinical work, Dr. Parikh is an elected member of several esteemed organizations, including the American Society for Clinical Investigation, the American Association of Physicians, and the American Clinical and Climatological Association.

His accolades include the NIH Outstanding Investigator Award, the Donald W. Seldin Young Investigator Award from both the American Society of Nephrology and the American Heart Association, as well as the STARs Award from the University of Texas System. Currently, he serves as the 59th President of the American Society of Nephrology (ASN).

During his presidency, ASN has made significant strides in advancing national research priorities through the Transforming Kidney Health Research initiative and has played a pivotal role in advocacy efforts that led to the passage of the Honoring our Living Donors (HOLD) Act.

Dr. W. P. Andrew Lee, Executive Vice President for Academic Affairs and Provost and Dean of UT Southwestern Medical School, expressed confidence in Dr. Parikh’s leadership. “Dr. Parikh’s commitment to all areas of our mission will further the Department of Internal Medicine and our institution’s national reputation for providing excellent clinical care, advancing meaningful research, and fostering a unique environment for biomedical education,” he stated.

Dr. Parikh’s appointment marks a significant milestone for UT Southwestern, as the institution continues to enhance its reputation as a leading center for medical education and research.

For more information, please refer to the official announcement from UT Southwestern.

Dr. Anushree Vichare has been appointed interim director of the Fitzhugh Mullan Institute for Health Workforce Equity at George Washington University, effective July 1.

Dr. Anushree Vichare, an accomplished Indian American researcher, has been named the interim director of the Fitzhugh Mullan Institute for Health Workforce Equity at George Washington University. She will officially assume her new role on July 1, succeeding Dr. Patricia “Polly” Pittman, who is retiring after co-founding the institute 11 years ago and serving as its director since 2020.

Vichare, an associate professor, began her academic journey in India, where she earned her Bachelor of Medicine, Bachelor of Surgery (MBBS) degree from MGM Medical College. She later moved to the United States to further her education, obtaining a Master of Public Health in epidemiology and a PhD in Healthcare Policy and Research from Virginia Commonwealth University.

Her extensive academic portfolio reflects her training and expertise, focusing on how Medicaid policies influence healthcare access, utilization, and outcomes for low-income populations. At George Washington University, Vichare’s work in the Department of Health Policy and Management examines the composition, diversity, and geographic distribution of health workers and their impact on the quality of care available to underserved communities.

Dr. Pittman praised Vichare’s contributions, stating, “Anushree has been an integral part of the leadership team, has a deep commitment to our mission and work, and, importantly, is adored by everyone who has the chance to work with her.”

In her current role, Vichare serves as an investigator on several externally funded research initiatives at the Mullan Institute. Her recent scholarship includes analyzing maternal health services, evaluating care delivery for Medicaid beneficiaries diagnosed with cancer, and exploring the impact of patient-clinician concordance on primary care utilization.

In addition to her research, Vichare co-leads the Health Workforce Diversity Initiative under the Social Mission Alliance at the institute. Her previous experience in health policy includes serving as the director of quality improvement for the American Gastroenterological Association, where she specialized in developing clinical performance metrics and quality measures for colonoscopy care.

University officials have indicated that Vichare will guide the strategic operations of the institute while a national search for a permanent director is conducted. Her leadership is expected to continue advancing the institute’s mission of promoting health workforce equity.

According to a university release, Vichare’s appointment reflects the institution’s commitment to maintaining strong leadership during this transitional period.

Cancer survivors practicing yoga experience significant improvements in mood, anxiety, and fatigue, according to a recent clinical trial published in the Journal of Clinical Oncology.

Cancer survivors often face ongoing physical and emotional challenges long after their treatment has concluded. A recent clinical trial has found that yoga may play a crucial role in alleviating some of these issues, particularly insomnia, fatigue, and mood disturbances that many survivors endure after remission.

The study, funded by the National Cancer Institute, involved 410 participants, including 204 cancer survivors receiving standard survivorship care alone and 206 survivors who incorporated the Yoga for Cancer Survivors (YOCAS) program into their treatment. The majority of participants were female breast cancer survivors.

YOCAS is a four-week intervention that combines two types of yoga: hatha, which is more active and traditional, and restorative, which is gentler and more passive. Both styles emphasize slow movements, breathing exercises, and mindfulness, as noted by the American Society of Clinical Oncology (ASCO).

During the trial, participants in the YOCAS group practiced yoga for an average of 180 minutes each week across three sessions. At the end of the study, those in the YOCAS group reported significant improvements in mood, anxiety, and fatigue, while the standard care group showed no such benefits.

“Additionally, improvements in insomnia stemming from YOCAS yoga may be mediated by changes in overall mood disturbance and fatigue,” the researchers stated in their findings.

Dr. Fumiko Chino, a cancer researcher and associate professor in breast radiation oncology at MD Anderson Cancer Center, emphasized the importance of this study. “It offers survivors, who are likely already managing multiple medications, a non-pharmaceutical solution for reducing four different side effects at once,” she said.

Dr. Timothy Pearman, director of supportive oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, expressed that he was not surprised by the study’s results. “Yoga is one of the most widely studied and validated interventions for managing cancer-related fatigue, mood disturbance, and overall physical health,” he noted.

Pearman shared that his wife, Jenny Finkel, is a yoga teacher who received her continuing education at Duke University’s integrative medicine program, which specializes in yoga for cancer patients. He highlighted the accessibility of yoga, stating, “All you need is a mat and someone to show you how to do it.” He also mentioned that yoga is highly adaptable, making it suitable for individuals with significant physical impairments.

In addition to addressing mood and fatigue, Pearman pointed out that yoga can help mitigate other physical symptoms related to cancer treatment, such as osteoporosis, an increased risk of cardiac problems, and issues with balance and stamina.

Shari Botwin, a licensed clinical social worker based in Pennsylvania and a thyroid cancer survivor, has seen firsthand the transformative effects of yoga. Specializing in trauma recovery, she noted that many cancer survivors face emotional challenges, including depression and survivor’s guilt. Botwin believes that yoga not only provides physical relief but also fosters a supportive environment among peers, some of whom are also cancer thrivers.

Botwin added that yoga can assist survivors in reframing their thoughts, especially those who have lost parts of their bodies due to cancer. “It supports us in moving into a place of self-compassion rather than shame and self-hatred,” she explained.

While yoga has shown promising benefits, Pearman emphasized that almost any type of exercise can be advantageous for cancer survivors. He advises his patients to engage in activities they enjoyed prior to their diagnosis. Furthermore, he noted that free yoga classes tailored for cancer survivors are widely available through various non-profit organizations.

As research continues to unveil the benefits of yoga for cancer survivors, it becomes increasingly clear that this practice can play a vital role in enhancing the quality of life for those navigating the aftermath of cancer treatment, according to Fox News Digital.

Former Attorney General Pam Bondi’s recent diagnosis of thyroid cancer highlights the importance of understanding the disease and its prognosis.

Former Attorney General Pam Bondi was diagnosed with thyroid cancer shortly after her departure from the Department of Justice last month. Bondi, 60, left her position in early April and is currently undergoing treatment and recovering, according to reports.

The thyroid is a butterfly-shaped gland located in the neck that produces hormones essential for regulating metabolism, energy levels, and the proper functioning of various organs, including the brain, heart, and muscles. The American Thyroid Association emphasizes the gland’s vital role in maintaining overall health.

Thyroid cancer, while relatively uncommon compared to other types of cancer, is still a significant health concern. As of 2023, more than one million individuals in the United States are living with the disease. The National Cancer Institute (NCI) projects that approximately 45,260 new cases will be diagnosed in 2026.

This form of cancer is more prevalent in women, but it can affect individuals of all genders. Risk factors include a family history of the disease, age (with those between 25 and 65 being more susceptible), and exposure to radiation.

Symptoms of thyroid cancer can manifest as lumps or swelling in the neck, difficulty breathing or swallowing, hoarseness, and pain during swallowing. Individuals experiencing these symptoms are advised to seek medical attention promptly.

If thyroid cancer is suspected, diagnosis can involve several methods. A laryngoscopy allows doctors to examine the voice box using a mirror or a thin tube-like instrument equipped with a light and lens. Blood tests can measure hormone levels, providing additional indicators of thyroid cancer. Imaging techniques such as ultrasounds and CT scans are also employed to identify tumors.

Treatment options for thyroid cancer typically include surgery, radiation, chemotherapy, and hormone therapy. A newer approach, immunotherapy, is currently being tested in clinical trials. According to Dr. Marc Siegel, a senior medical analyst at Fox News, surgery is the primary treatment method, often followed by regular monitoring and thyroid hormone replacement therapy.

In cases where the entire thyroid gland must be removed, patients will require hormone replacement to compensate for the loss of natural thyroid function. Dr. Siegel notes that radioactive iodine may be used in more aggressive cases, although it is not always necessary.

The prognosis for thyroid cancer is generally favorable, largely depending on the cancer’s response to treatment. Some types of thyroid cancer are milder and grow more slowly than others. The stage of the cancer at diagnosis also plays a crucial role in determining outcomes.

The most optimistic scenario occurs when a surgeon can completely excise the tumor during surgery. Additionally, doctors will consider whether this is a new diagnosis or a recurrence of previously treated cancer.

As Bondi navigates her treatment journey, her case underscores the importance of awareness and understanding of thyroid cancer and its implications for those diagnosed.

For more information on thyroid cancer and its treatment options, consult resources provided by the National Cancer Institute and other health organizations.

According to Fox News, Bondi’s diagnosis serves as a reminder of the need for vigilance regarding health and wellness.

Kyle Busch’s death was attributed to severe pneumonia that progressed to sepsis, highlighting the dangers of untreated respiratory infections, according to his family.

Kyle Busch, the two-time NASCAR Cup champion, passed away at the age of 41 due to severe pneumonia that escalated into sepsis, as confirmed by a statement from his family. The announcement, made on Saturday, detailed that Busch died on Thursday following a brief hospitalization for what was described as a “severe illness.”

The family’s statement explained, “The medical evaluation provided to the Busch Family concluded that severe pneumonia progressed into sepsis, resulting in rapid and overwhelming associated complications.” This tragic case emphasizes the serious risks associated with pneumonia, particularly when symptoms are ignored or worsen quickly.

Pneumonia is a respiratory infection that fills the lungs with fluid, making it difficult to breathe. It can be caused by various pathogens, including bacteria, viruses, or fungi. Common symptoms of pneumonia include cough, fever, chills, chest pain, and shortness of breath.

Prior to his death, Busch reportedly suffered from a sinus infection that deteriorated into pneumonia. Dr. Marc Siegel, a senior medical analyst for Fox News, noted that “this upper respiratory sinus infection progressed to pneumonia.” He further explained that bacterial pneumonia is typically more severe than its viral counterpart.

Dr. Siegel also pointed out that the physical stress associated with racing simulators—designed to replicate the intense G-forces experienced by drivers—could exacerbate already inflamed lungs during the recovery process from pneumonia, although direct research on this topic remains limited.

In severe cases, pneumonia can lead to the infection spreading into the bloodstream, resulting in a life-threatening inflammatory response known as sepsis. This is particularly dangerous for vulnerable patients or when treatment is delayed. Sepsis can quickly lead to tissue damage, organ failure, and even death if not addressed promptly.

<p”The body reacts to this severe lung infection by making inflammatory chemicals. It’s the immune system revving up,” Dr. Siegel explained. “But as with many things in the body, the immune system can hurt more than help.” As sepsis progresses, it can cause a drop in blood pressure and hinder the delivery of oxygen to the body’s tissues, potentially resulting in lactic acidosis—a dangerous buildup of lactic acid in the bloodstream.

Organ failure is a significant risk, particularly affecting the kidneys, according to Dr. Siegel. “The kidneys fail, toxins from the kidneys build up, blood pressure goes down, fever goes up, the lungs fail—something called ARDS,” he warned. Acute respiratory distress syndrome (ARDS) occurs when inflammation causes fluid to leak into the lungs, making it difficult for oxygen to reach the bloodstream.

Common warning signs of sepsis include confusion, rapid breathing, extreme weakness, low blood pressure, fast heart rate, and bluish or mottled skin, as noted by the Centers for Disease Control and Prevention (CDC).

Doctors stress that sepsis is a medical emergency, as patients can deteriorate rapidly within hours. Those at higher risk for severe pneumonia and sepsis include older adults, smokers, individuals with chronic lung diseases, diabetes, weakened immune systems, or those who have recently experienced viral infections.

This tragic incident serves as a reminder of the potential severity of pneumonia and the importance of seeking timely medical attention for respiratory infections, especially for those at greater risk.

According to Fox News, the circumstances surrounding Kyle Busch’s death highlight the critical need for awareness and prompt treatment of pneumonia and its complications.